CA-125/CEA RATIO AS A PROGNOSTIC FACTOR IN TYPE II ENDOMETRIAL CANCER: A SINGLE INSTITUTE EXPERIENCE
World Cancer Research Journal, cilt.9, 2022 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 9
- Basım Tarihi: 2022
- Doi Numarası: 10.32113/wcrj_202212_2453
- Dergi Adı: World Cancer Research Journal
- Derginin Tarandığı İndeksler: Scopus
- Anahtar Kelimeler: Type II Endometrial Cancer, CA-125, CEA Ratio, Prognosis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: Type II (non-endometrioid) endometrial cancer is less common with an incidence of 10%-20%. It has an aggressive clinical course with heterogeneous clinic pathological features. The aim of this study is to evaluate prognostic factors and survival outcomes in type II en-dometrial cancer. Patients and Methods: Patients aged over 18 years with diagnosis of Stage IA-IVB type II en-dometrial cancer were included to the study. Between 2013 and 2019, a total of 76 patients were evaluated retrospectively. Results: Median overall survival (OS) was 25 months while median disease-free survival (DFS) was 22 months. Median DFS was 25 months (95% CI: 14.71-35.28) in patients with negative lymph nodes while it was 10 months (95% CI: 6.88-13.11) in patients with positive lymph nodes (p=0.017). Median OS was 28 months (95% CI: 23.05-32.95) in patients with a ratio of CA-125/CEA<25 while it was 16 months (95% CI: 5.19-26.80) in those with a ratio of CA-125/CEA≥25 (p=0.02). Patients with an Eastern Cooperative Oncology Group performance score (ECOG PS) <2 at the time of diagnosis had a signif-icantly longer OS than ECOG PS≥2 [median 29 months (95% CI: 22.99-35.94) vs. 15 months (95% CI: 0.33-29.66); p=0.024]. In multivariate Cox regression analysis CA-125/CEA (HR:1.70, 95% CI: 1.01-2.83, p=0.042) was independent risk factor for OS. Conclusions: CA-125/CEA ratio may have prognostic significance in type 2 endometrial cancer, but it needs to be supported by randomized clinical trials.